Cannabis use disorder: from neurobiology to treatmentBernard Le Foll, Victor Tang, Sergio Rueda, Leanne Trick, Isabelle BoileauCannabis has been legalized for medical and recreational purposes in multiple countries. A large number of people are using cannabis and some will develop cannabis use disorder (CUD). There is a growing…
|
https://www.jci.org/articles/view/172887https://doi.org/10.1080/17434440.2024.2404962 |
https://journals.sagepub.com/doi/full/10.1177/07067437241261488 |
Factors associated with presentation to the emergency department during an intensive post-discharge intervention in patients with substance use disordersHelena Kim, Pamela Kaduri, Leslie Buckley, Victor Tang, Narges BeyraghiEarly identification of patients with substance use disorders (SUDs) with a higher risk of emergency department (ED) presentations after being discharged can be useful. We performed a chart review of patients from the Intensive Recovery Discharge Team (IRDT) program, which provides two weeks of outpatient… |
https://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.20230886 |
Five Years After Cannabis Legalization, Is It Time to Ease Restrictions on Promotion?Created by Jean-François Crépault, Sergio Rueda, Victor TangIn the spring of 2024, the federal government is expected to report on its legislative review of the Cannabis Act (2018). One of the most contentious issues is whether to relax restrictions on cannabis promotion… |
https://www.mdpi.com/2076-3425/14/4/356 |
https://www.cmaj.ca/content/196/10/E346 |
https://doi.org/10.1007/s40429-024-00564-0 |
A systematic review and meta-analysis of neuromodulation therapies for substance use disordersCreated by Dhvani Mehta, Angela Praecht, Heather Ward, Marcos Sanches, Maryam Sorkhou, Victor Tang, Vaughn Steele, Colleen Hanlon & Tony George.While pharmacological, behavioral and psychosocial treatments are available for substance use disorders (SUDs), they are not always effective or well-tolerated…https://doi.org/10.1016/j.brs.2024.01.008 |
Identifying clinical predictors of response to repetitive transcranial magnetic stimulation for smoking cessation: Secondary analysis of a multicenter RCTVictor Tang, Laurie Zawertailo, Peter Selby, Abraham Zangen, Dhvani Mehta, Tony George, Bernard Le Foll, Kristina Gicas. Matthew Sloan, Scott VeldhuizenTobacco smoking remains a leading cause of morbidity and mortality worldwide. While evidence-based treatments exist for nicotine dependence, many patients do not respond to or cannot tolerate them. Repetitive Transcranial Magnetic Stimulation (rTMS) is a novel, non-invasive neuromodulation treatment that stimulates parts of the brain involved in addiction [1]. Recently, the Brainsway H4 deep TMS coil was cleared by the FDA and Health Canada for the treatment for… |
https://www.cmaj.ca/content/196/6/E187 |
...